Drugs / Apadenoson
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00162071 | Jul 2005 → Mar 2006 | myocardial ischemia | Forest Laboratories | Terminated | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT01313572 | Aug 2011 → Apr 2012 | coronary artery disorder | Forest Laboratories | Terminated | No outcome recorded |
| Phase 3 | NCT00990327 | Nov 2009 → Apr 2012 | coronary artery disorder | Forest Laboratories | Terminated | No outcome recorded |
| Phase 3 | NCT00380198 | Jul → Nov 2006 | coronary artery disorder | Forest Laboratories | Terminated | No outcome recorded Stop: Business |
| Phase 3 | NCT00162084 | Apr 2005 → Mar 2006 | myocardial ischemia | Forest Laboratories | Terminated | No outcome recorded Stop: Business |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | apadenoson | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00162071 ↗ |
| Known as | BMS-068645 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1950649 ↗ |
| Known as | DWH-146E | ChEMBL registry synonym — accepted as the source's own label CHEMBL1950649 ↗ |
| Known as | Stedivaze | ChEMBL registry synonym — accepted as the source's own label CHEMBL1950649 ↗ |
| Action | Activate | “Adenosine A2a receptor agonist” CHEMBL1950649 ↗ |
| Modality | Small molecule | — CHEMBL1950649 ↗ |
| Route | Intravenous | “Apadenoson single bolus IV injection 100 or 150 ug” NCT00990327 ↗ |
| Target | ADORA2A | “Adenosine A2a receptor agonist” CHEMBL1950649 ↗ |